Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry

The clinical characteristics of sJIA suggest that it is distinct from other forms of JIA, leading to the contention by some that sJIA should be separated from other forms of JIA and labelled as an autoinflammatory disease [7]. [...]sJIA is regarded as an autoinflammatory disease due to the good response to inhibition of interleukin (IL)-1ß or IL-6 [8, 9]. The patients cohort treated with etanercept (ETA) had been observed prospectively as well, although ETA had been approved earlier and was the only available biologic agent for treatment of patients with JIA for several years. Since more than... Mehr ...